Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for FREE ACCESS to this landmark database

Sign In to gain access to subscriptions and/or personal tools.
Clinical Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sharma, R.K.
Right arrow Articles by Rezvani, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharma, R.K.
Right arrow Articles by Rezvani, E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Clinical Evaluation of the Anorexic Activity and Safety of 42-548 in Children

Report of a Clinical Trial

R.K. Sharma

Department of Pediatrics, Nassau County Medical Center, East Meadow, N. Y. 11554

P.J. Collipp

Department of Pediatrics, Nassau County Medical Center, East Meadow, N. Y. 11554

I. Rezvani

Department of Pediatrics, Nassau County Medical Center, East Meadow, N. Y. 11554

J. Strimas

Department of Pediatrics, Nassau County Medical Center, East Meadow, N. Y. 11554

V.T. Maddaiah

Department of Pediatrics, Nassau County Medical Center, East Meadow, N. Y. 11554

E. Rezvani

Department of Pediatrics, Nassau County Medical Center, East Meadow, N. Y. 11554

A double-blind study comparing the safety and efficacy of 42-548, a new, synthetic tricyclic appetite suppressant, with a placebo was started with 116 obese adolescent patients. All patients received a fixed daily dose of one tablet, one hour before the noon meal, for 12 weeks. A reduced caloric intake was prescribed initially and the patients were instructed to stay on this diet. 42-548 produced an average weight loss of 18.9 lb. at the end of the study, and the placebo a loss of 11.8 lb., a statistically significant difference. The medication was relatively well tolerated.

Clinical Pediatrics, Vol. 12, No. 3, 145-149 (1973)
DOI: 10.1177/000992287301200308
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?